Drug Trial Radar · NCT06101342
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
181
Actual
Start
Dec 13, 2023
Primary completion
Jul 27, 2026
Study completion Jan 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- HIV Prevention Trials Network; National Institute on Drug Abuse (NIDA); National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Oct 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). The primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID.
Conditions
- Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir InjectionDrug
Administered subcutaneously
Lenacapavir TabletDrug
Administered orally
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN): LEN Plasma concentration at the End of the Dosing Interval (Week 26)Time frame: Week 26
- PK Parameter: Ctrough for LEN: LEN Plasma concentration at the End of the Dosing Interval (Week 52)Time frame: Week 52
- Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: First dose date up to 30 days post last dose at Week 52
- Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities with LEN and F/TDFTime frame: First dose date up to 30 days post last dose at Week 52
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCLA Vine Street Clinic
Los Angeles, California
UCSD AntiViral Research Center (AVRC)
San Diego, California
University of Miami - Converge Miami Building
Miami, Florida
Johns Hopkins Medicine Institute for Clinical and Translational Research, Clinical Research
Baltimore, Maryland
Rutgers New Jersey Medical School, Department of Medicine
Newark, New Jersey
ICAP at Columbia University- Bronx Prevention Center
The Bronx, New York
University of Pennsylvania, Division of Infectious Diseases Penn Prevention Research Unit
Philadelphia, Pennsylvania
Houston AIDS Research Team CRS
Houston, Texas
West Virginia University
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.